Hypertrophic cardiomyopathy guideline update: Mayo Clinic's perspective

Mayo Clinic medical experts in hypertrophic cardiomyopathy, Jeffrey B. Geske, M.D., Steve R. Ommen, M.D., and Hartzell V. Schaff, M.D., discuss the recent publication of the "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy."
They review the top changes to the guideline, including the introduction of a cardiac myosin
inhibitor, mavacamten, for support of people with symptomatic obstructive hypertrophic cardiomyopathy (HCM); the evolved guidelines for healthy levels of exercise; the formal split in sudden cardiac death risk assessment between children and adults living with HCM; and new advice on more frequent screening for individuals who have risk factors for atrial fibrillation.
Learn more, www.mayoclinic...
From Mayo Clinic to your inbox, sign-up for free: mayocl.in/3e71zfi
Visit Mayo Clinic: www.mayoclinic...
Like Mayo Clinic on Facebook: / mayoclinic
Follow Mayo Clinic on Instagram: / mayoclinic
Follow Mayo Clinic on X, formerly Twitter: x.com/MayoClinic
Follow Mayo Clinic on Threads: www.threads.ne...